1,25(OH)2D3 723
131I-MIBG 565
18F-FDG-PET/CT 1157, 2973
5-azacytidine 1775
5-fluorouracil 1904, 2175, 2396
abiraterone 1079
abiraterone acetate 325
ABO blood group 2462
ABVD chemotherapy 2560
ACE-inhibitors 249
acetylation 2675
acquired resistance 1876
actinomycin D 2954
acute lymphoblastic leukaemia 2189
acute promyelocytic leukaemia 2819
ADAM17 2217
ADCs 1570
adenoid cystic carcinoma 1117
adherence 1172, 1513
adiponectin 872
ADIPOQ 872
ADIPOR1 872
adiposity 751
adjuvant chemotherapy 545
adoptive T-cell therapy 658
advanced gastric cancer 2079
advanced hepatocellular cancer 888
advanced melanoma 1451
advanced NSCLC 1467
aerosol delivery 1775
aflibercept 1735
AFP routine test 1657
African American 1945
age 780, 1717, 2941
ageing 219
age-period 1310
AGO2 3116
AKT 1198, 1586
alcohol 859, 1945
ALDH1 109
ALK expression 2735
ALK gene amplification 2735
ALK mutation 2735
allogeneic haematopoietic stem cell transplantation 2523
anaplastic astrocytoma 844
anaplastic lymphoma kinase 3084
androgen 1279
androgen receptor 950, 1271
angiogenesis 360, 1230, 1243, 2072, 2597, 2842
angiogenesis inhibitor 538
angiopoietin-2 2072
animal models 1579
anti-androgen 983
anti-angiogenic 1725
anticancer therapy 1056
anti-platelet therapy 1921
antisense oligonucleotide 2579
anti-tumour immunity 2167
AP-1 2248
apoptosis 164, 342, 433, 2189, 2434, 2685, 2696, 2792, 2853, 3034
aprepitant 859
AQUA 1859
aromatase 100
aromatase inhibitor 589, 1522, 2331
aromatase inhibitor resistance 1537
arsenic 235
asbestos 1965
ASNS 14
aspirin 249
attendance 597
AURKA 2445
Aurora kinases 2607
autophagy 164, 1040, 2434, 2597
Bacillus Calmette-Guérin 2106
basal-like breast carcinoma 444
baseline sum longest diameter 1476
bcg 1460
BCG immunotherapy 2106
BerEP4 2217
bevacizumab 552, 1408, 1725
bexarotene 2566
biliary adenocarcinomas 915
biliary tract cancer 2665
biochemical recurrence 641
bioconductor and R packages 1394
biological interaction 2005
biomarkers 1, 147, 379, 395, 482, 530, 641, 694, 1013, 1562, 1782, 2096, 2228, 2356, 2445, 2765, 2864
birth cohort 2467
bispecific antibodies 934
bisphosphonates 795
bladder cancer 50, 121, 1040, 1460, 1586, 2106
blood biomarkers 1657
BLT2 351
BMP 1805
BMPRIA 1805
BMSC 1198
body mass index 289, 589, 751, 1522, 1899, 2894
boiled coffee 1344
bone markers 121
bone marrow 1264
bone marrow-derived cells 360
bone metastasis 3014
borderline ovarian tumours 2774
bowel 1504
BRAF 559
BRAF mutation 2833
BRCA mutation carriers 777
BRCA1 2347, 2724
BRCA2 2724
breaking bad news 2507
breast biopsy 242
breast cancer, 42, 100, 109, 154, 257, 351, 582, 589, 597, 866, 872, 1157, 1172, 1291, 1302, 1310, 1513, 1522, 1528, 1543, 1556, 1676, 1693, 1829, 1876, 1886, 1926, 1945, 2035, 2175, 2331, 2472, 2783, 2792, 2798, 2965, 3034
breast cancer incidence 1296
breast cancer screening 242, 597
breast cancer therapy 1147
breast density 2331
breast neoplasms 1165
breast reconstruction 1181
buccodental toxicities 1750
Burkitt's lymphoma 280
C35 965
C609T 1325
c-ABL 1100
CAF 926
caffeine 1908
CAIX 1859
cancer anorexia-cachexia 1867
cancer cell migration 1829
cancer chemoprevention 1
cancer genetics 497
cancer genome analysis 827
cancer incidence 1989
cancer inflammation 739
cancer prevalence 219
cancer registration 2875
cancer stem cell 379, 950, 1252, 2619
cancer survival 42
cancer survivors 891
cancer treatment 1549
cancer-associated fibroblasts 3049
cancer-specific survival 1899
capecitabine 1408, 1744
carboplatin 538, 859, 1072, 1467
carcinogenesis 3057
cardiovascular damage 891
cardiovascular disease 60
care closer to home 1549
case–control studies 795, 1360, 2472, 2904
castration-resistant prostate cancer 325, 1079, 1711, 2579
Caucasian 1821
CCL19 1100
CCR7 1100
CD4 helper T lymphocytes 2155
CD44 variant 9 379
CD8 2705
CDH-1 994
CDH-2 994
CDK 2356
Cdk inhibition 2378
CDK6 2751
CDKN2A 2207
CEA 934
cediranib 943, 2765
celebrity 1192
cell cycle 3042
cell death biomarkers 2560
cell invasion 2810
cell membrane 195
cells of origin 1599
cellular motility 422
central tumour 184
cerebellum 844
cerebral cortex 844
cervical cancer 35, 92, 615, 1192, 1504, 2778
cervical cancer screening 1766
cetuximab 1117
changing presentation 2115
checkpoint receptors 2629
chemokine 1100, 2412
chemokines and chemokine receptors 1579, 2424
chemoprotection 2954
chemoprovention 249
chemoradiotherapy 1467
chemo-resistance 92, 965
chemotherapeutic 2131
chemotherapy 552, 891, 1117, 1243, 1414, 1428, 1549, 1904, 2175, 2340, 2554, 2954, 2980
chemotherapy response 370
Chernobyl 2286
childhood cancer 1373, 2880
childhood leukaemia 2880
children 844, 2515, 3084
chimeric antigen receptors 658
chloroquine 2597
choice 1181
cholangiocarcinoma 915, 2665, 3092
chondrosarcoma 1214
chordoma 2574
chromaffin cell tumour 565
chromogranin A 1414
chromosomal translocation 299
chromosome 16q 512
chromosome 1q 512
chromosome 6p 512
chronic 1504
chronic liver disease 1344, 1997
chronic lymphocytic leukaemia 1287
chronic myeloid leukaemia 1593
circulating microRNA 641
circulating tumour cells 1223, 2829
cisplatin 891, 915, 1904, 2096, 2548, 2980
cJun 3116
classification 1599, 1886
clear cell carcinoma 1899
clinical decision support systems 1147
clinical practice guidelines 1147
clinical trial costs 2051
clinical trials 897
clinicopathologic 1302
CLL 2434
c-met 1271
c-Met inhibitor 2619, 2803
CNS tumour risk 289
coffee 1352, 1908
coffee preparation 1344
cohort study 265, 761, 2496, 2886, 2917, 2924, 2933
cohort study timing 1310
cola 1908
collagen Type XI a 1 3049
colon cancer 138, 395, 994, 1023, 2175
colonoscopy 1437
colorectal cancer 24, 114, 131, 138, 307, 408, 667, 694, 807, 814, 934, 1004, 1013, 1338, 1352, 1408, 1420, 1437, 1618, 1636, 1725, 1744, 1782, 1839, 2207, 2445, 249, 2735, 2765
colorectal liver metastases 2396
colorectal neoplasms 387, 1243, 2005
colposcopy 1766
combination of platelet count and
neutrophil to lymphocyte ratio 401
combination study 943
combination therapy 1085
communication 836
communication skills 2507
community 1549
comorbidity 265, 2489
competing risks 1974
compliance 1513
computed tomography 1445
computer-assisted image analysis 1839
Concholepas haemocyanin 1488
concordance 2875
conjunctiva 1981
consequences of cancer treatment 2121
cooperation 1056
copy number changes 2347
cost attribution 2051
cost-effectiveness 1172, 2295, 2533
Coxsackievirus and Adenovirus
receptor 1848
CpG island methylator phenotype 1004
CRC 694
C-reactive protein 2066, 2316
CrkL 1100
CSCs 1876
CT26 tumour 2167
CTL 462
curative treatment 272, 1609
cutaneous T-cell lymphoma 2566
cyclophosphamide 1725
cyclotherapy 2954
CYP2C19 polymorphism 2803
cytokine 2072
cytology 603, 1192
cytotoxic T lymphocytes 462, 2705
dacarbazine 1451
DBC1 2675, 3042
DCIS 100
decaffeinated coffee 1908
decision making 780, 2295
deep remission 2998
deleterious BRCA1/2 mutation 1072
dendritic cells 462, 1488
Denmark 2489
dental hygiene 1367
dermatology 497
detection method 2833
development 1
diabetes mellitus type II 2924
diagnosis 694, 807, 2027
diagnostic tool 2646
diagnostic workup 242
diastolic heart function 891
DICER1 2744
diet 257, 1914, 2904
diethylstilboestrol 1079
differential expression 1848
diffuse large B-cell lymphoma 312
diffusion-weighted MRI 615, 1562
disease progression 121
disease-specific survival 1093
disparities 1302
disseminated tumour cells 1264
disulfiram 1876
DNA damage 2378, 3023
DNA damage repair 68, 3042
DNA damage response 1063
DNA methylation, 530, 1394, 3073
DNA repair proteins 68
DNA-PKcs 2654
DNp73 965
docetaxel 1085
donor lymphocyte infusion 2523
dose escalation 651
dose–response meta-analysis 1926
dovitinib 2309
doxorubicin 1206
DPEP1 694
DPYD 2347
DR5 2685
drug delivery 2142, 2368
drug resistance 2607
drug sensitivity 1063, 1599
drug therapy 60
DTH 1488
DUSP6 1063
dynamin 1 1867
E6*I mRNA 172
early breast cancer 2453
early detection 603, 1437, 2489
early detection lung cancer 530
early recurrence 1648
E-cadherin 2248
ecological study 235
EGFR 482, 1063
EGFR inhibitors 1063
EGFR mutation 1821
elderly 852, 1717, 1744
electronic patient-reported outcome
monitoring 2301
emergency 2027
emotion 836
EMT 307, 1666, 2248, 2587
endocrine therapy 589, 1537, 2959
endometrial cancer 215, 704, 756, 761, 1498, 1504, 1699, 1703, 1760, 1908, 1914
endoplasmic reticulum stress 433, 3034
EndoPredict 2959
endoscopic procedure 379
endovaginal 615
England 235, 2058
enteritis 1504
environmental exposure 2886
environmental radiation 2880
EpCAM 2217
EPHA2 2142
EpICD 2217
epidemiology 257, 289, 756, 769, 795, 1287, 1318, 2005, 2880
epidermal growth factor 207
epidermal growth factor receptor 1821, 2155
epidermal growth factor-like domain 7 1243
epigenetic 2266
epigenetic alteration 807
epigenetics 408
epigenome 1775
epithelial ovarian cancer 1685
epithelial-to-mesenchymal transition 184, 307
ERCC1 2096
erlotinib 1786, 2803
E-selectin 3014
ESFT 195
esophageal cancer 1367
estradiol 1522
ethinylestradiol 1537
ethnicity 780
ETV1 1625
European Organisation for Research
and Treatment of Cancer
QLQ-C30 852
evaluation 2987
evening appointment 597
everolimus 1482, 1755
evolutionary game theory 1056
Ewing sarcoma 2696, 658
ex vivo 1223
excess treatment costs 2051
exemestane 2453
exogenous hormones 1954
extended therapy 589
external gamma radiation 1989
extracellular ATP 1666
extracellular matrix proteins 3049
EZN-4176 2579
fallopian tube cancer 603
false-positive referral 2044
family history 788
female 859
fertility 615, 2778
FFPE 2404
FGFR1 2248
FGFR3 50
FHL2 114
fibrinogen 1123
filtered coffee 1344
fine-needle biopsies 2646
first treatment evaluation 2998
fish 756
FKBP51 signalling 2189
flavonoids 1914
fluorodeoxyglucose positron emission
tomography-computed
tomography 1445
focal adhesion turnover 2810
folate 2175
FOLFOX/XELOX 2765
follicular lymphoma 1287
follow-up 29, 312, 623, 866, 1766
food 2904
four-and–a-half LIM domains protein 2 114
FOXO3 protein 387
FOXO3a 1198
fragile sites 2347
FSH 1522
FTO 872
fucosyltransferase 3014
fulvestrant resistance 2751
functional characterisation 2228
Fyn 1214
gallbladder cancer 915
GalNAc-T3 472
GalNAc-T6 472
gamma-glutamyltransferase 610
gamma-glutamyltranspeptidase
(GGT) 610
gastric cancer 379, 2199, 2217, 2619
gastrointestinal cancer 2829
gastrointestinal stromal tumour 1403, 2309, 2574
gefinitib 1786
gemcitabine 915, 2566
gemcitabine resistance 502
gemcitabine-refractory 920
gene amplification 299
gene expression 1599, 2228, 2286
gene fusion 1051
gene methylation 1775
genetic 714
genetic testing 777
genomics 1636
GEP-based score 676
geriatric oncology 272
germ cell and embryonal 60
germ cell tumours 2744
g-glutamyl hydrolase 2175
GIST 1403, 1625
Glasgow Prognostic Score 24
Gleason grade 2115
glioblastoma 164, 433, 844, 2853
GLTSCR2 2199
glucose-regulated proteins 370
glycolysis 976
GNA11 493
GNAQ 493
goserelin 582
GPER 2751
graft-vs-tumour effect 2523
granulosa cell tumour of the ovary 29
Great Britain 1965
growth arrest 2587
growth factors 1056
GRP78 433
g-secretase inhibitor 667
GSTM3 3105
guideline adherence 1147
gynaecological cancer symptoms 882
gynaecological oncology surgery 623
H. pylori eradication 2323
haematological malignancy 565, 2886
haemoptysis 1609
hair colour 747
Hashimoto's thyroiditis 2496
HBV infection 2917
HCC-ART score 1657
HCV infection 2917
HDACi 676
head and neck cancer 172, 1093, 2096, 2629
head and neck squamous cell
carcinoma 482, 1859, 2155, 2973, 3049
health inequalities 780
health status disparities 1318
health-care rationing 888
health-related quality of life 852
heat-shock proteins 370
heat-shock transcription factor-1 1648
help-seeking 882
hematopoietic stem cell
transplantation 2515
hepatic resection 1428
hepatitis 2924
hepatitis B 573
hepatitis C virus 2481
hepatocellular carcinoma 14, 83, 573, 1031, 1198, 1648, 1657, 1904, 2072, 2481, 2654
HER1/EGFR 2453
HER2 1157, 2453, 2829, 2453
hereditary breast cancer 154, 2724
HES1 1023
heterogeneity 1056
HEY1 1023
Hif1 2131
Hif1a 83
high-grade glioma 844
histone modifications 299, 994, 3073
HIV 1974, 1981
HNSCC 2636
Hodgkin's lymphoma 280, 2560
homing 3014
homologous recombination 3042
hormonal therapy 1513
hormone refractory 1711
hormone replacement therapy 1895, 1954
hot flashes 1291
HOTAIR 2266
HPV 172, 2096
HPV genotyping 2941
HPV infection 184
HPV prevalence 2941
HPV screening 2941
HPV types 2941
HSF1 2654
hSWI/SNF 2751
human cytolytic fusion proteins 1570
human papillomavirus 1766, 1981, 2941
human tumour xenografts 1562
HUNT 1310
hyaluronidase 1556
hydrophilic 318
hypersensitivity 1072
hypertension 2924
hypothyroidism 215
hypoxia 50, 1795, 1859, 2597
hypoxia-regulated miRNAs 50
hysterectomy 1760
IAPs 2368
IFN-b 1198
IFN-g 76
IGF1R/mTOR signalling pathway 2189
ILK 2842
image analysis 1618
imatinib 1403, 1408, 1725, 2309, 2574
immune cells 1839, 2207
immune infiltration 1031, 1618
immune phenotype 76
immunocytochemistry 1264
immunocytokines 1206
immunohistochemistry 1252, 1618, 1839, 1886, 2665, 2833
immunomagnetic selection 1264
immunosuppression 280, 1974
immunotherapy 1570, 2155, 2412
immunotoxins 1570
incidence 219, 2467
indolent ductal carcinoma in situ 2035
induced gene 100
inequalities 1181
inflammation 147, 395, 416, 1839, 2316, 2665
inflammation-based prognostic
system 401
inflammatory breast cancer 318
ING4 2842
inguinofemoral lymphadenectomy 2533
injury 1504
insulin resistance 2792
intensity hypothesis 1965
interaction 265
interferon 2481
interleukin-6 131
interlukin-2 2412
internal plutonium exposure 1989
intra-arterial 2980
invasion 1137, 1666, 3049
invasive front 184
iodine-131 2286
ionising radiation 2286
ipilimumab 8
IRF-1 76
irinotecan 1420, 1428, 2619, 3067
Irinotecan sucrosofate 920
irradiation 1829
Ishak stage 573
ITGA6 2636
Jade Goody 1192
Jewish 777
JWA 2842
Kashmir 1367
Ki67 1859, 2792
KIT 559, 1625
Koehne's risk classification 1428
KRAS 3057, 3067
KSR1 2675
lactate dehydrogenase 2066
LAMC2 2636
laryngeal cancer 172
L-asparaginase 14
late relapse 2959
LC-MS/MS 1867
lead time 2014
lenvatinib 538
letrozole 100
leukaemia 2886
lifetime drinking 1945
LINE-1 408
LINE-1 elements 3073
lipophilic 318
liposome 920
liver cancer 1344, 1997
liver metastasis 2445
liver neoplasm 1904
liver-limited disease 1428
local inflammatory response 131
localised prostate cancer 272
locally advanced 2554
locoregional recurrence 866
logistic regression 2880
long non-coding RNAs 2266
long-term 545
long-term survival 1428
low-dose aspirin 1921
LPCAT1 1279
lung adenocarcinoma 1100, 1609
lung cancer 538, 1467, 1699, 1775, 1954, 2066, 2301, 2404
lung cancer epidemiology 1974
lung cancer prognosis 1974
lung cancer screening 530
lung neoplasm 2058
lung progression 1579
lymph node density 2087
lymph node metastasis 1685, 1693
lymph node ratio 1165
lymphocytes subsets 1676
lymphoma 1556
lysine-specific demethylase 1 994
lysyl oxidase 2237
magnetic resonance imaging 1528, 2987
major histocompatibility complex
class II 2155
malignancy 2714
malignant clone expansion 2819
malignant melanoma 3116
malignant mesothelioma 1813
malnutrition 1093
mammaglobin B (SCGB2A1) 462
mammary gland 1829
mammographic screening 2467
mammography 597, 2331
MAPK 493
markers 714
Markov model 2035
Maspin 1636
matrix degradation 422
matrix metalloproteinase (MMP) 731
maxillary sinus 2980
Mayak radiation workers 1989
MC1R 747
MCF-7 breast cancer cells 2751
MCG 101 1867
MDM2 2199
MDR 2356
MDR1 drug resistance 2131
mean survival 1735
meat 756
meat mutagens 756
median survival 1735
Mediterranean diet 1360
meetings 2295
MEK 1562
melanocortin-4 receptor 1867
melanoma 8, 265, 433, 444, 497, 2412, 2833, 2842
melatonin 83
memory T cells 1488
meningioma 289, 1051
menopause 1291, 1945
mesothelioma 552
mesothelioma latency 1965
MET 1271, 2248
meta-analysis 2894
metabolic response 1157
metabolic syndrome 60
metabolism 976
metastasis 994, 1109, 1137, 1230, 1543, 1636, 1666, 1685, 1829, 2266, 2554, 2636, 2714, 2810, 307, 3092
metastatic breast cancer 1537
metastatic colorectal cancer 1428, 3067
metastatic phenotype 1618
metastatic renal cell carcinoma (mRCC) 2998
metastatic/advanced disease 909
metformin 2792
methionine 1926
methotrexate 2175
methylxanthines 1908
metronomic 1725
metronomic cyclophosphamide 957, 2574
microarray 207, 1394, 1599
microenvironment 1648
microRNA 502, 641, 714, 1243, 1271, 2724, 2744, 2853, 3092
microRNA profiling 2724
microRNAs 452, 2646
microsatellite instability 1004, 3057
migration 207
miR-100 50
miR-106a 452
miR-106b 2323
miR-125b 2853
miR-17 1625
miR-20a 1625
miR-21 2323
miR-221 2714
miR-222 1625, 2714
miR-29s 2636
miR-302c 723
miR-320c 502
miR-34c 1271
miR-375 92
miR-520c 723
miR-591 452
miR-92a 731
miRNA 2189
miRNA 2404, 3116
modelling 2035
moderately emetogenic chemotherapy 859
module validation study 852
molecular diagnosis and prognosis 2404
molecular diagnostic technique 1693
molecular diagnostics 530
monitoring 1528
monocarboxylate transporter-4 1648
mortality 2467
mouse models 658
MRI 2965
MRP-1 195
mTOR 164, 686, 1786
mTOR inhibitors 1755
mTORC1 2389
mTORC2 2389
mucosa-associated lymphoid tissue 1 207
mucositis 2515
multi-disciplinary team 1445, 2295
multidrug resistance 351
multikinase inhibitor 888
multilevel analysis 1437
multiple myeloma 676
multiple treatment lines 2301
multitumour tissue microarray 1848
mutation 1703
mutation analysis 1593
mycosis fungoides 2566
myeloablative conditioning 2523
myeloid leukaemia 1895
nab-paclitaxel 926
nasopharyngeal carcinoma 788, 2462, 2987
National Health Insurance Research
Database 2933
natural compounds 2587
neoadjuvant chemotherapy 1157, 1528, 2792, 2798, 2965
neoplasia 1192
neoplasm metastasis 387
neoplasms 60, 1318
nephroureterectomy 1130
Netherlands 2467
nested case–control study 1997
neural stem markers 444
neuroblastoma 433
neuroendocrine tumour 565, 1414
neutrophil-lymphocyte ratio 24, 401, 1755, 1813
next-generation sequencing 827
NF-kB 76
NGR-hTNF 360
NKG2D ligands 723
nomogram 1109, 1130, 1498, 2774
non-Hodgkin's lymphoma 280, 312
non-invasive imaging 1562
non-melanoma skin cancer 235, 1287
non-persistence 1513
non-small cell lung cancer 530, 545, 1223, 1252, 1264, 1476, 1821, 1974, 2803
Notch 667
notch signalling 1023
NQO1 1325
NRAS 559
nuclear hormone receptor 299
nuclear power 2880
nuclear translocation 76
nulliparity 769
nursing 2121, 3005
nut consumption 2911
nutlin-3 2685, 2954
nutrient 2904
obesity 589, 751, 814
obstructive uropathy 2933
occupational exposure 1965
oesophageal adenocarcinoma 370
oesophageal cancer 1445, 2894
oesophageal squamous cell carcinoma 1109, 2266
oestrogen 100
oestrogen receptor 2453
oncofetal fibronectin 1206
oncogenic mutation 493
ophthalmology 497
oral cancer 207
oral cavity 2087
oral contraceptives 1895, 1954
oral dysplasia 2864
oral health 1367
oral squamous cell carcinoma 1859
oropharyngeal cancer 2904
OSNA 1693
OSSN 1981
osteoporosis/drug therapy 795
osteosarcoma 1579, 2142, 2228, 2607
outreach 1549
ovarian cancer 452, 462, 603, 610, 751, 769, 965, 1072, 1786, 2368, 2744
overall survival 121, 318, 1093, 1760
overdiagnosis 2014
oxaliplatin 1408, 1420, 2396
oxidation 983
p16INK4a 172, 2207
p21 2378
P2Y2 receptor 1666
p38MAPK 2853
p53 2434, 2675, 2685, 2696, 2853, 2954
paclitaxel 92, 538, 1482, 1876
paclitaxel resistance 351, 452
PALB2 154
palliative chemotherapy 1467, 2301
pancreatic cancer 416, 502, 739, 920, 1360, 1795, 1805, 2424, 2911, 2917, 2924
pancreatic intraepithelial neoplasia
(PanIN) 2424
parent 836
parity 769
pathological complete response 1157, 2705
pathways 2027
patient experience 780
patient survival 2665
patient-reported 623
patients preferences 633
PAX3/7-FOXO1 3084
pazopanib 1040, 1414
PCNA 2378
PDA 926
pelvic floor 3005
penis cancer 2554
pentraxin family 739
pepsinogen 2323
perimenopausal 582
peritoneum 1685
pERK 915
persin 3034
personalised diagnostics 704
personalised medicine 866
PET–CT 312
P-glycoprotein 351
Pgp 195
pharmacodynamic 897, 1782
pharmacokinetics 1744
pharmacology 2356
phase I clinical trial 897, 1043, 1085, 2560, 2579, 2803
phase II 897
phase III randomised controlled trial
651
phase-1b 1482
phosphoethanolamine 2819
phosphorylated Pyk2 1252
photodynamic therapy 976, 2167
photoreceptor 512
physical activity 761, 814
physical therapy 3005
PI3K 1085
PIAS4 1795
PICT1 2199
pigmentation traits 747
PIK3CA 1085
plasma 3067
plasma DNA 807
platelet-activating factor 1279
platinum-based chemotherapy 1223,
2378, 2548
PLCO 1352
plitidepsin 1451
pN1 1165
Polycomb 299, 1699
polymorphism 957, 1325, 2331 3105
pooled analysis 1954
population-based 272
positron-emission tomography 1414
post-mastectomy radiation therapy 1165
postmenopausal women 761
postoperative complications 623, 1310, 2894
post-treatment surveillance 2973
prediction 3067
prediction of drug sensitivity 676
predictive biomarker 14
predictive biomarkers 1243
predictive factor 1165
premenopausal 582
preoperative chemotherapy 1693
pretargeting 934
pre-therapeutic 1223
PRIMA-1Met/APR-246 2696
primary care trusts 888
primary systemic therapy 2705
Pro187Ser 1325
proanthocyanidins 1914
processing 1394
proctopathy 1504
prognosis 14, 147, 1004, 1013, 1031, 1123, 1137, 1252, 1264, 1338, 1609, 1685, 1782, 1839, 215, 2259, 2266, 2316, 2340, 2445, 2462, 2714, 2778, 2842, 3067, 3105, 395, 416, 472, 573, 610, 788, 2066, 2864
prognostic factors 29, 866, 1165, 1428, 1813, 2714, 3057
prognostic marker 138, 2654
prognostic model 332
prognostic/predictive marker 2765
progression 1460
progression-free survival 318, 1760
proliferation 2189, 2207
propensity score 1904
prospective cohort study 751, 1344, 1352, 2911
prostate cancer 641, 651, 747, 950, 957,
983, 1271, 1279, 1666, 1711, 2115, 2121, 2131, 3014, 3023
prostate cancer treatment 633
prostate cancer vaccine 1488
pro-survival signaling 2587
proteomics 704, 1636, 2142, 2378
PRRX1 307
PSA 1488
PSEN2 2217
psychological distress 1373
Pt-(GpG) DNA adducts 1223
PTEN 1586
PTEN expression 1703
public goods 1056
Pyk2 1252
pyrosequencing 2833
QALYs 1172
Q-TWiST 8
qualitative 1181
quality of care 1147
quality of life 1543, 2301, 2783, 3005
questionnaire 1543
race 1945
radiation 1504, 2340, 3023
radiation associated breast
angiosarcoma 2340
radical prostatectomy 272
radical trachelectomy 2778
radionuclide imaging 934
radionuclide therapy 934
radiotherapy 272, 651, 1093, 1117, 2980, 3005
radon 235
rapamycin 1586, 2597
rare tumour 3057
re-attendance 2044
rectal cancer 3073
recurrence 379, 1338, 1460, 1498, 1513, 2973, 3073
red hair 747
reduced intensity conditioning 2523
referral 242, 2027
registry 1403
regulatory T cells 2167, 2629
relapse 29
relapse risk 2774
renal cancer 332, 686
renal cell carcinoma 121, 147, 472, 714, 1123, 1137, 1230, 1750, 1755, 1899, 2389, 3105
renal cell tumours 2646
repeated testing 2833
reporting practices 897
representative cell line 1599
research costs 2051
resection 573
residents 2507
resistance 1230, 1593
response 2798
response evaluation criteria in solid
tumours 1476
response monitoring 2965
retina 512
retinoblastoma 512
reverse phase protein array (RPPA) 370
reversine 2810
Reversion-inducing Cysteine-rich
protein with Kazal motifs
(RECK) 731
rhabdomyosarcoma 2523
ribosomal s6 protein kinase 4 1137
risk 1914, 3105
risk assessment 1460
risk factor 769, 1360, 2904
risk prediction model 1296
risk profiles 2115
risk score 2481
rituximab 1556
RMS 3084
RNAi 3116
RNA-Seq 1051
RNAseq 1599
RO4929097 943
Ron antibody 482
Ron receptor 482
route 2027
RPL11 2199
rs1800566 1325
RTK 3084
S-1 545, 1420
S-1 plus cisplatin therapy 2079
safety 1408
salivary adenoid cystic carcinoma 444
sarcoma 1206, 1717
sarcopenia 325
SCCC 1981
schwannoma 289
screening 35, 249, 603, 1192, 2014
screening history 35
screening mammography 2044
second malignancies 1287
second-line 920
SEER program 1318
self-reporting 2875
senescence 2207
sensitivity to apoptosis 1063
sentinel lymph node biopsy 2533, 2783
serous carcinoma 603
SerpinB5 1636
serum 641
serum vitamin D 1997
service provision 1181
sex cord-stromal tumours 2744
shear-wave ultrasound 2798
shiftwork 2472
shRNA 3116
sialyl-6-T 2106
sialyl-Tn 2106
side population 2619
sigma-2 receptor 2368
signal pathways 714
signal transducer and activator of
transcription 3 (STAT3) 731
signature genes 1599
SILAC 2675
sinonasal melanoma 559
sinusoidal obstruction syndrome 2396
siRNA 3116
sirolimus 1786
skeletal-related events 121
Smac 2368
SMAD4 1805
small intestine adenocarcinoma 3057
small-cell lung cancer 1482
SMARCC1 502
smoking 814, 2489
Snail 2248
socioeconomic factors 2489
soft tissue sarcoma 909, 2316
sorafenib 342, 888, 915, 2072
SOX10 444
SOX9 1023
spindle cell 2259
splicing 195
squamous 2087
squamous cell carcinoma 1981, 2259
squamous cell lung cancer subtypes 1599
Src 1214
SS18-SSX 1 2279
SS18-SSX 2 2279
staging system 2987
standardized incidence ratios 229
STAT1 138
STAT3 83, 138
statin 249, 318
stem cells 950, 2587, 3023
stratification 1886
stroma 926
strontium 2886
STS 1717
subcutaneous administration 1556
sunitinib 332, 1040, 1403, 1750, 2309
supplements 257
supportive care 888, 2121
surgery 42, 1109, 2340
surveillance imaging 312
surveillance PET 312
surveys 780
survival 147, 195, 215, 219, 257, 493, 565, 788, 814, 1302, 1338, 1476, 1676, 1703, 1805, 2005, 2027, 2058, 2066, 2087, 2462, 2548, 2735, 2894, 2973, 3073
survival after surgery 401
survival analysis 29, 2279
survivorship 1373, 2121
symptom survey 882
synergistic antitumour 342
synergy 2005
synovial sarcoma 2279
systemic analysis 704
systemic inflammatory response 131,
401
Taiwan 2933
tamoxifen 582, 1172, 2453, 3034
targeted therapy 332, 909, 1755, 2142, 2607
taxane 2131
T-cell lymphoma 280
tea 1352, 1908
telomerase 497
temsirolimus 1711, 2389
tenovin-6 2434
testicular 2744
testicular cancer 891
testicular tumours 68
testosterone 950
tetrandrine 342, 2864
TFII-I 3042
TGF b 2167
therapeutic target 1579
therapy 2714
thoracic surgery 2058
thrombocytosis 401
thyroid cancer 2286
thyroid gland 215
thyroid-stimulating hormone 215
tissue microarray 138, 387
tivantinib 2803
TKI 1040
TNF signalling 422
TNF-a 76
TNFAIP8 1685
toluidine sulphonamide 2131
tooth loss 1367
torisel 1711
TP53 1214, 2199
trabectedin 1717
trachelectomy 615
TRAIL 2685
training 2507
transcription factor 3042
transforming growth factor-b 207
transplantation 280
trastuzumab 1556
treatment cost savings 2051
treatment costs 2051
treatment sequencing 1079
trends 242, 1318
triadic consultation 2507
trials 1
triple-negative breast cancer 2347
truncation mutation 299
TSU-68 2079
tubal ligation 1291
tuberclosis infections 229
tuberculosis 2933
tumorigenicity 2228
tumour angiogenesis 2237
tumour antigens 2155
tumour differentiation 2424
tumour dimensions 1476
tumour endothelial cells 2237
tumour glycosylation 2106
tumour invasion 422
tumour microenvironment 2412
tumour morphology 154
tumour necrosis 131
tumour progression 3049
tumour response 1528, 2356
tumour shrinkage 2998
tumour size 1476, 2035
tumour suppressor 2636
tumour suppressor gene 807
tumour targeting 360
tumour-associated antigen 1031
tumourigenesis 3092
tumour-infiltrating lymphocyte 1013, 2629, 2705
tumour-infiltrating macrophage 1013
tumour-necrosis factor 1206
tumour-stage characteristics 1921
two-dimensional electrophoresis 1867
tyrosine kinase inhibitor 538, 686, 1230, 1403, 1593, 1755, 1821
UGT 950
UK 2875
UKGOSOC 623
ulcerative colitis 694
unknown primary 1318
uPAR 2714
upper urinary tract 1130
urinary irritative symptoms 3005
urinary tract cancer 2933
urokinase-type plasminogen activator
system 2714
urologists 633
urothelial carcinoma 1130, 2548
uterine cervical neoplasms 2489
uveal melanoma 493
validation 1123, 1130, 1296, 1460, 1498, 2774
vascular invasion 472, 1609
vascular targeting 360, 1206
VEGF 83, 957
VEGF-targeted therapy 2998
VELOUR 1735
vinflunine 2548
vinorelbin 1467
viral oncogenesis 172
vitamin B12 1926
vitamin B6 1926
vitamin C 257
vitamin D 747
vulva 2259
vulvar cancer 184, 2533
VX-680 2607
waiting times 42
weekend appointments 597
weight gain 872, 1310
weight loss 1093
whole-body magnetic resonance
imaging 658
whole-genome microarray 2286
Wnt 667
wortmannin 1586
XPF 2096
young women 35, 109, 1302
ZD6474 164
ZM447439 2607
ZSTK474 1786
Change history
10 December 2013
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Keyword Index for Volume 109. Br J Cancer 109, 3145–3150 (2013). https://doi.org/10.1038/bjc.2013.773
Published:
Issue Date:
DOI: https://doi.org/10.1038/bjc.2013.773